This protocol applies to female patients with androgenetic alopecia and clinical or biochemical evidence of hyperandrogenism in whom a previous treatment course did not achieve the goal of stopping hair loss progression.
The patient is a woman with androgenetic alopecia and clinical or biochemical evidence of hyperandrogenism. This combination defines the specific sub-population addressed here.
A previous course of oral Cyproterone acetate, prescribed in combination with an oestrogen, did not achieve its primary target: prevention of progression of androgenetic alopecia — hair loss was not stopped.
This protocol represents the structured next step following that failure.
For suitable patients in this setting, a surgical approach may be considered — access the full protocol for the complete eligibility criteria and regimen details.
The primary goal is cosmetic recovery of the affected areas, with outcome assessment at 9–12 months.
Oral CPA can be considered to prevent progression of AGA in women with clinical or biochemical evidence of hyperandrogenism.
Surgery especially follicular unit transplantation (FUT) can be considered in female patients with sufficient donor hair.
The final result can be evaluated at 9–12 months.
DOI: 10.1111/jdv.14624
View source ↗